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Abstract
Background: The spider-venom peptide v-hexatoxin-Hv1a (Hv1a) targets insect voltage-gated calcium channels, acting
directly at sites within the central nervous system. It is potently insecticidal when injected into a wide variety of insect pests,
but it has limited oral toxicity. We examined the ability of snowdrop lectin (GNA), which is capable of traversing the insect
gut epithelium, to act as a ‘‘carrier’’ in order to enhance the oral activity of Hv1a.
Methodology/Principal Findings: A synthetic Hv1a/GNA fusion protein was produced by recombinant expression in the
yeast Pichia pastoris. When injected into Mamestra brassicae larvae, the insecticidal activity of the Hv1a/GNA fusion protein
was similar to that of recombinant Hv1a. However, when proteins were delivered orally via droplet feeding assays, Hv1a/
GNA, but not Hv1a alone, caused a significant reduction in growth and survival of fifth stadium Mamestra brassicae
(cabbage moth) larvae. Feeding second stadium larvae on leaf discs coated with Hv1a/GNA (0.1–0.2% w/v) caused $80%
larval mortality within 10 days, whereas leaf discs coated with GNA (0.2% w/v) showed no acute effects. Intact Hv1a/GNA
fusion protein was delivered to insect haemolymph following ingestion, as shown by Western blotting. Immunoblotting of
nerve chords dissected from larvae following injection of GNA or Hv1a/GNA showed high levels of bound proteins. When
insects were injected with, or fed on, fluorescently labelled GNA or HV1a/GNA, fluorescence was detected specifically
associated with the central nerve chord.
Conclusions/Significance: In addition to mediating transport of Hv1a across the gut epithelium in lepidopteran larvae, GNA
is also capable of delivering Hv1a to sites of action within the insect central nervous system. We propose that fusion to GNA
provides a general mechanism for dramatically enhancing the oral activity of insecticidal peptides and proteins.
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Introduction
Arthropod venoms contain a rich diversity of compounds
including a significant number of neurotoxic disulphide-rich
peptides. Most spiders prey exclusively upon insects and other
arthropods and thus it is not surprising that many spider-venom
peptides have been shown to modulate the activity of arthropod
ion channels. One such example is v-hexatoxin-Hv1a (formerly v-
atracotoxin-Hv1a; hereafter referred to as Hv1a), the best-studied
member of a family of 36–37 residue insecticidal neurotoxins
isolated from the venom of the Australian funnel web spider
Hadronyche versuta. Hv1a specifically inhibits insect but not
mammalian voltage-gated calcium channels [1,2,3]. Structurally,
Hv1a comprises a disordered N-terminus (residues 1–3), a
disulfide-rich globular core (residues 4–21), and a highly conserved
C-terminal b hairpin (residues 22–37) that protrudes from the
disulphide-rich core and contains the key residues for insecticidal
activity [4,2]. The three disulphide bonds form an inhibitor cystine
knot motif that provides many spider-venom peptides with
extreme chemical and thermal stability, as well as resistance to
proteases [5,6].
Hv1a is highly toxic by injection towards many different insect
pests including species from the Orders Lepidoptera, Coleoptera,
Dipteran and Dictyoptera [7–10]. Its potency and phyletic
specificity makes Hv1a an ideal candidate for development of
novel bioinsecticides. However, whilst toxic by injection, Hv1a
and many other insecticidal venom peptides are typically
ineffective, or at least much less potent, when delivered orally
and this is thought to be due to ineffective delivery of the toxins to
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system (PNS). This lack of oral activity clearly limits their potential
application as bioinsecticides. In order to access the nervous
system after oral delivery, peptide toxins must be resistant to
proteolytic degradation in the insect gut, and they must be able to
cross the insect gut epithelium. The latter factor is thought to be
the major limitation in oral toxicity of protein and peptide toxins.
The mannose-specific lectin GNA (Galanthus nivalis agglutinin;
snowdrop lectin) is resistant to proteolytic activity in the insect gut.
Moreover, following ingestion, GNA binds to gut epithelial
glycoproteins and is transported into the haemolymph [11]. This
property of GNA can be used to transport peptides across the
insect gut [12]. Previous results have shown that the oral
insecticidal activity of peptides derived from the venom of spiders
and scorpions can be dramatically enhanced by fusing them to
GNA [13–16], presumably because GNA mediates their delivery
to the hemolymph where the toxins can subsequently reach their
sites of action in the CNS or PNS.
The present paper reports on the insecticidal activity of a fusion
protein comprised of Hv1a linked to the N-terminus of GNA. We
show that the Hv1a/GNA fusion protein, expressed in yeast and
purified from culture supernatant, is biologically active by
injection, indicating that fusion to GNA does not compromise
the insecticidal activity of Hv1a. Whereas Hv1a alone was not
orally active against the cabbage moth Mamestra brassicae, the
Hv1a/GNA fusion protein had significant oral activity against this
lepidopteran crop pest. Moreover, for the first time, we present
direct evidence for binding of orally delivered GNA to the CNS of
lepidopteran larvae. This suggests that in addition to providing a
mechanism for delivery of peptide toxins across the insect gut,
GNA may further facilitate toxin activity by delivering covalently
attached toxins to the CNS of insects. Thus, fusion to GNA
provides a general mechanism for dramatically enhancing the oral
activity of insecticidal peptide neurotoxins.
Results
Synthetic Gene and Fusion Protein Construct Assembly
A synthetic gene encoding the mature Hv1a amino acid
sequence was assembled using a series of overlapping oligonucle-
otides, with codon usage optimised for expression in yeast
(Table 1). Following assembly, the coding sequence was amplified
by PCR and ligated into a yeast expression vector (derived from
pGAPZaB) that contained a sequence coding for the mature GNA
polypeptide (amino acid residues 1–105). The 37-residue Hv1a
peptide was fused to the N-terminus of GNA via a tri-alanine
linker sequence as depicted in Fig. 1A. The Hv1a/GNA construct
was cloned such that the N-terminal yeast a-factor prepro-
sequence would direct the expressed protein to the yeast secretory
pathway. The final Hva1/GNA fusion protein is predicted to
contain an additional two alanine residues at the N-terminus (after
removal of the prepro- sequence) and terminate at residue 105 of
the mature GNA protein, giving a predicted molecular mass of
16.36 kDa. The Hv1a/GNA-pGAPZaB construct was cloned into
E. coli and the coding sequence was verified by DNA sequencing.
Expression and Purification of Recombinant Hv1a/GNA
Fusion Protein
DNA from a verified Hv1a/GNA-pGAPZaB clone was
linearised, transformed into the protease-deficient P. pastoris strain
SMD1168H, and selected on antibiotic containing plates. Ten
clones were analysed for expression of recombinant protein by
Western blot (using anti-GNA antibodies) of supernatants derived
from small-scale cultures (results not shown). This allowed
selection of the best expressing clone for fusion protein production
by bench-top fermentation.
For fusion protein production, P. pastoris cells were grown in a
BioFlo 110 laboratory fermenter. Recombinant GNA was
expressed and purified as previously described [14]. The Hv1a/
GNA fusion protein was purified from clarified culture superna-
tant by hydrophobic interaction chromatography followed by a
second gel-filtration step to remove high molecular weight
contaminating yeast proteins. Two major proteins of ,20 kDa
and ,14.5 kDa were recovered following fermentation and
purification of recombinant Hv1a/GNA (Fig. 1B). The 20-kDa
protein migrates at a higher than expected molecular weight than
the 16.36 kDa predicted for intact fusion protein. However,
Western blot analysis (Fig. 1C) using anti-GNA and anti-Hv1a
antibodies confirmed that the higher molecular weight protein
represents intact fusion protein as it is immunoreactive with both
anti-GNA and anti-Hv1a antibodies. The lower molecular weight
band, which does not show positive immunoreactivity with anti-
Hv1a antibodies, represents GNA from which the Hv1a peptide
has been cleaved. Analysis of samples taken during fermentation
confirmed that cleavage of the fusion protein occurs during
expression and not during purification (results not shown). Intact
Hv1a/GNA fusion protein was expressed at levels of ,50 mg/l of
culture supernatant. The ratio of intact fusion protein to cleaved
GNA was consistently 2:1 as judged by SDS-PAGE gels and
Western blots.
Injection Toxicity of Hv1a/GNA and Hv1a
The biological activity of Hv1a/GNA was verified by injection
of 5–20 mg of purified fusion protein into fifth stadium M. brassicae
larvae (40–70 mg). Injections of comparable molar amounts of
recombinant Hv1a (2.3–9.2 mg) were also conducted. Larval
mortality occurred over a period of 4 days (Table 2) but was
observed predominantly within the first 48 h following injection.
Larvae injected with higher doses of fusion protein (10 mg and
above) or toxin alone (4.6 mg and above) displayed symptoms of
paralysis, and survival was significantly reduced as compared to
the control treatment (Kaplan–Meier survival curves; Mantel–Cox
log-rank tests; P,0.001). Levels of mortality were comparable
between fusion protein injected and toxin injected treatments (e.g.,
80% mortality for larvae injected with 92 mg toxin/g insect
compared to 90% mortality for larvae injected with 100 mg toxin
as a component of fusion protein/g insect).
Oral Toxicity of Hv1a/GNA and Hv1a
Several experiments were performed to assess whether fusion
to GNA was able to improve the oral toxicity of Hv1a. First,
fifth stadium M. brassicae larvae were fed daily for four days on
droplets containing 40 mg of purified fusion protein or 9.6 mg
Hv1a (Fig. 2A). Ingestion of daily droplets of fusion protein was
found to result in a complete cessation of larval feeding
evidenced by the significantly reduced mean weight recorded for
this treatment as compared to the control group. After four
days, 40% of the treated larvae were dead and the remaining
insects did not survive to pupation. In striking contrast, no
reduction in larval growth as compared to the control BSA
treatment was observed for larvae fed on droplets containing
Hv1a, indicating that the oral toxicity of Hv1a is dramatically
enhanced by fusion to GNA.
In a second assay, fourth stadium larvae were fed on a single
droplet containing 40 mg of Hv1a/GNA (Fig. 2C) and this was
shown to cause a reduction in larval growth as compared to
control-fed larvae over a period of approximately six days. By
day 7, control larvae had attained their maximum weight after
Orally Active Insecticidal Fusion Protein
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pre-pupal phase (day 6–7). By contrast, larvae that had ingested
a single Hv1a/GNA-containing droplet exhibited a reduced
growth rate reaching maximal weight at day 8–9, after which
larvae pupated.
The oral toxicity of the Hv1a/GNA fusion protein was further
investigated by feeding 2nd instar M. brassicae larvae on cabbage
Figure 1. Protein production and purification. (A) Schematic of construct encoding Hv1a/GNA showing predicted molecular masses of Hv1a
and GNA as well as the total mass of the Hv1a/GNA fusion protein including the tri-alanine linker region and the additional two alanine residues at
the N-terminus. (B) Coomassie blue stained SDS-PAGE gel (17.5% acrylamide) of recombinant Hv1a/GNA and GNA following purification by
hydrophobic interaction and gel filtration chromatography. The approximate loading of protein (mg) is indicated above each lane, while the lane
marked ‘‘M’’ contains molecular weight standards (Sigma SDS-7). (C) Composite of Western blots of recombinant proteins using (i) anti-GNA and (ii)
anti-Hv1a antibodies. The approximate protein loading (ng) is denoted above each lane. FP denotes Hv1a/GNA fusion protein.
doi:10.1371/journal.pone.0039389.g001
Table 1. Oligonucleotide sequences used for assembly and amplification of a synthetic gene encoding for the mature Hv1a toxin.
Coding strand
Oligo 1:
59-GCATCTCCAACTTGTATTCCATCTGGTCAACCATGTCCATATAATGAAAATTGTTGT
Oligo 2:
59-TCTCAATCTTGTACTTTTAAAGAAAATGAAAATGGTAATACTGTTAAAAGATGTGATGC
Complementary strand
Oligo 3:
ACGTCGTAGAGGTTGAACATAAGGTAGACCAGTTGGTACA
Oligo 4:
GGTATATTACTTTTAACAACAAGAGTTAGAACATGAAAATTT
Oligo 5:
CTTTTACTTTTACCATTATGACAATTTTCTACACTACGCCGG
Primers for amplification of full-length sequence
Forward primer:
59 TAACTGCAGCATCTCCAACTTGTATTCC
Reverse primer:
59 TTAGCGGCCGCATCACATCTTTTAACAG
Underlined bases depict restriction sites (PstIa n dNot I) used for ligation of the full-length fragment into the yeast expression vector pGAPZaB.
doi:10.1371/journal.pone.0039389.t001
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might be more representative of situations in which Hv1a is
employed on crops as a foliar bioinsecticide. The survival of larvae
was significantly reduced when insects were fed on Hv1a/GNA-
coated discs (Fig. 3) such that 15% and 20% of larvae remained
after 10 days of exposure to discs coated with Hv1a/GNA at
concentrations of 0.2% w/w and 0.1% w/w, respectively. In
contrast, 80% survival was recorded for larvae reared for 10 days
on discs coated with 0.2% w/w GNA, which was not significantly
different to the 90% survival recorded for the control (no added
protein) treatment. Fusion protein treatment survival curves were
significantly different to both the GNA and control treatments
(Kaplan-Meier; Mantel–Cox log-rank tests; P,0.001). Exposure
to Hv1a/GNA-coated discs also retarded larval growth in
surviving larvae. The reduction in growth was dose-dependent,
so that by day 7 the average weight of surviving larvae fed on 0.2%
or 0.1% w/w Hv1a/GNA was reduced by 90% and 76%,
respectively, compared to the control treatment. GNA was also
shown to reduce larval growth, so that by day 7 the average weight
of larvae fed 0.2% w/w GNA was reduced by 45% compared to
the control treatment.
Delivery of Ingested Hv1a/GNA to the Circulatory System
and Binding of Injected Hv1a/GNA and GNA to the
Central Nerve Chord
We have previously shown that GNA is capable of
transporting covalently attached peptides across the insect gut
into the hemolymph [11,13]. To determine if the toxic effects
observed in oral bioassays were attributable to GNA-mediated
delivery of Hv1a to the circulatory system of M. brassicae larvae,
haemolymph was extracted from insects fed on diets containing
Hv1a/GNA and analysed for the presence of fusion protein by
Western blotting using anti-GNA antibodies. A representative
blot, depicted in Fig. 4A, confirms immunoreactivity of a major
band corresponding to the molecular weight of intact fusion
protein in samples from larvae fed Hv1a/GNA, but not control
insects. As shown previously in Fig. 1C, fusion protein samples
contain two GNA-immunoreactive bands corresponding to
intact fusion protein and GNA from which the Hv1a peptide
has been cleaved. Thus, the presence of a second smaller
immunoreactive band in haemolymph samples from fusion
protein fed larvae suggests uptake of both intact Hv1a/GNA
and cleaved GNA, or cleavage of intact fusion protein after
absorption in the insect gut. Cross-reactivity and poor sensitivity
of the anti-Hv1a antibodies did not allow the detection of fusion
protein or toxin when these antibodies were used to probe
Western blots of larval haemolymph.
The above results indicate that the major reason for the
improved oral activity of Hv1a when it is fused to GNA is the
ability of this lectin to mediate delivery of Hv1a to the insect
hemolymph. However, we also wondered whether GNA might
also be able to enhance delivery of Hv1a to its sites of action in
the insect nervous system. To investigate if GNA is able to bind
to the nerve tract of lepidopteran larvae, intact nerve chords
were dissected from insects injected with either GNA or Hv1a/
GNA and analysed by Western blotting using anti-GNA
antibodies. Nerve chords and haemolymph samples, pooled
from 3–6 insects, were typically extracted 3–12 h following the
injection of 10–20 mg of GNA or Hv1a/GNA. Fig. 4B shows
positive immunoreactivity of bands corresponding in size to
GNA and intact Hv1a/GNA fusion protein in both nerve chord
and haemolymph samples taken from injected insects, which
suggests that GNA is able to bind to the nerve tract of
lepidopteran larvae. Bands corresponding to GNA or Hv1a/
GNA fusion protein were not observed in nerve tissue extracted
from insects fed on GNA or Hv1a/GNA (at 2.5 mg/5 g wet wt.
diet), presumably due to the levels of bound protein being
below the limits of detection of the anti-GNA antibodies.
Further evidence of the ability of GNA to bind to the central
nerve chord was sought by visualisation of nerve chords
dissected from insects that had been injected with, or fed on,
fluorescently-labelled GNA or Hv1a/GNA. Control treatments
were FITC-labelled ovalbumin or FITC alone. The visualisation
of nerve chords dissected following injection was carried out on
four separate occasions where typically 2–3 nerve chords per
treatment were analysed and comparable results obtained. A
composite showing different regions of M. brassicae nerve chords
from different treatments is presented in Fig. 5. Low
background fluorescence was observed in control FITC alone
and FITC-labelled ovalbumin nerve chords. By contrast,
fluorescence was observed along the entire length of the nerve
tracts, including the terminal brain ganglion, of insects injected
with FITC-labelled GNA or Hv1a/GNA. Fluorescence ap-
peared to be predominantly localised to the nerve chord sheath.
Reduced fluorescence was observed in instances where FITC-
labelled GNA had been pre-incubated in the presence of
mannose, suggesting that localisation to the nerve chord was
mediated by binding of GNA to mannose-containing polypep-
tides in the nerve chord epithelium. However, binding was not
completely inhibited under the conditions tested (results not
shown). Similar results were obtained in experiments where
Table 2. Mortality recorded for fifth stadium M. brassicae larvae 72 h after injection of different concentrations of recombinant
Hv1a and Hv1a/GNA.
Treatment Dose (mg/g insect) (Hv1a equivalents) Mortality (%) Sample No.
Control – 0 20
Hv1a 184 90* 10
92 80* 10
46 20 10
Hv1a/GNA 100 90* 20
50 45* 20
25 0 20
Doses of injected Hv1a/GNA are expressed as Hv1a equivalents to allow a direct comparison with the Hv1a treatment and are based on a mean larval weight at injection
of 50 mg. Asterisks denotes significant difference in survival between control and toxin treatment (P,0.0001).
doi:10.1371/journal.pone.0039389.t002
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although the levels of fluorescence were lower than those
visualised from injected larvae (Fig. 5). This was attributed to
lower levels of GNA and Hv1a/GNA being delivered to the
circulatory system following ingestion as compared to the levels
present in injected insects.
Discussion
Hva1 Retains Insecticidal Activity when Fused to GNA
Hv1a is the most studied member of the v-HXTX-1 family of
insecticidal toxins isolated from the venom of the Australian funnel
web spider Hadronyche versuta [9]. It has been shown to be highly
toxic by injection to a wide range of insects [1–3,9]. Toxins of the
v-HXTX-1 family contain three conserved disulphide bonds that
form an inhibitor cystine knot motif that is critical for toxin
activity. We therefore used Pichia pastoris, a host capable of
correctly forming disulphide cross-links, to create a fusion protein
containing Hv1a linked to the N-terminal region of the lectin
GNA. The use of a secretory signal enabled facile purification of
recombinant fusion protein from fermented culture supernatants.
As observed previously for SFI1/GNA and ButaIT/GNA [13,14],
some cleavage of the Hv1a/GNA fusion protein occurred during
expression, despite the use of a protease-deficient host strain.
Differences were observed in the degree of proteolysis and
cleavage patterns (as assessed by Western blot analysis) for the
three fusion proteins although all appear to be prone to cleavage
between the N-terminal region of the toxin sequence and the C-
terminus of GNA. For Hv1a/GNA, a single cleavage site is
indicated by the presence of two major proteins in purified
fractions, corresponding to intact fusion protein and GNA protein
from which the Hv1a toxin has been cleaved. Nevertheless, the
majority of expressed Hv1a/GNA was present as intact fusion
protein, as evidenced by molecular mass on SDS-PAGE gels and
positive immunoreactivity with anti-GNA and anti-Hv1a antibod-
ies. The C-terminus of Hv1a (residues 33–36) includes the
sequence VKRC, which is similar to the signal sequence (EKRE)
present in the a-factor signal sequence expression vector that is
cleaved between R and E by the KEX2 gene product. Further
analysis is required to establish whether this or another site is the
precise location of cleavage between the Hv1a peptide and GNA
protein.
Previously reported values for toxicity by injection of recombi-
nant and synthetic Hv1a are highly variable, even when
considering different species of the same genus. For example, the
ED50 reported for synthetic Hv1a against the cotton bollworm
Heliothis armigera is 3 nmol/g [7], which is more than 10-fold higher
than the PD50 dose of 250 pmol/g reported for the tobacco
hornworm Heliothis virescens [8]. In our hands, the doses of injected
recombinant Hv1a and Hv1a/GNA required to induce flaccid
paralysis and significant mortality of fifth stadium M. brassicae
larvae were comparable (50–100 mg toxin/g insect equivalent to
12–25 nmoles/g), suggesting that Hv1a activity is not significantly
compromised by C-terminal linkage to GNA. However, these
doses are somewhat higher than those typically reported for
recombinant Hv1a (e.g., LD50 of 77 pmol/g and 716 pmol/g
respectively for the housefly Musca domestica and lone star tick
Amblyomma americanum; [10]). Differences in the toxicity of Hv1a
towards different species must, to a large degree, be determined by
differences in the ability of the toxin to disrupt ion channel
function. However, variability also derives from the use of different
toxicity parameters (e.g., LD50,E D 50 and PD50), different sources
of toxin (i.e. synthetic, recombinant or native peptide) and the
suitability and/or ease of injection. In previous studies we assessed
the injection toxicity of the spider toxin SFI1 and the scorpion
toxin ButaIT, when fused to GNA, towards larvae of the tomato
moth Lacanobia oleracea and the cotton leafworm Spodoptera littoralis.
Whilst SFI1/GNA was more toxic than ButaIT/GNA towards
L. oleracea [12,14], ButaIT/GNA was more toxic than SFI1/GNA
towards S. littoralis [16]. In addition, ButaIT/GNA was found to be
more generally toxic than SFI1/GNA when tested against a range
Figure 2. Droplet feeding assays. (A) Mean weight of fifth stadium
M. brassicae larvae fed daily sucrose droplets containing either
9.2 mg Hv1a, 40 mg Hv1a/GNA, or 40 mg bovine serum albumin (BSA,
control). Significant differences between Hv1a/GNA and control or Hv1a
treatments were observed at days 1–4 (ANOVA Tukey post hoc; day 1,
P=0.0003; days 2–4, P,0.0001). (B) Image depicts larvae assayed in (A);
control larvae on the left (BSA- and Hv1a-fed larvae) and Hv1a/GNA-fed
larvae on the right. (C) Mean weight of fifth stadium M. brassicae larvae
fed a single sucrose droplet containing either 40 mg Hv1a/GNA or
control 40 mg BSA. Differences in mean weights between control and
fusion protein treatments were significant from day 1 to day 6 of the
assay (t-test; P,0.05).
doi:10.1371/journal.pone.0039389.g002
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coleopteran adults and larvae and dictyopteran nymphs [16].
Variability in the susceptibility of different insect species prevents
strict comparative analysis. However, we note that the amounts of
Hv1a/GNA necessary to cause toxicity to M. brassicae larvae (50–
100 mg toxin/g insect causing .50% mortality) are comparable to
the amounts required for other GNA-toxin fusion proteins (i.e.,
SFI1/GNA: 20–125 mg toxin/g insect causing .50% mortality in
Lacanobia oleracea [12]; ButaIT/GNA: 50–135 mg toxin/g insect
causing .50% mortality in Spodoptera littoralis [16]).
Fusion to GNA Massively Enhances the Oral Toxicity of
Hv1a
Hv1a has been reported to be orally active against ticks, and it
appears to be orally active against the lepidopteran Spodoptera
littoralis and Helicoverpa armigera when expressed in plants [10,17].
However, we found that Hv1a alone was not orally active when
fed to fifth stadium M. brassicae larvae. This is consistent with the
observation that the LD50 for Hv1a in the sheep blowfly Lucilia
cuprina is 90-fold lower when the toxin is delivered per os compared
with injection (V. Herzig and G.F.K, unpublished data). In striking
contrast, the Hv1a/GNA fusion protein was orally toxic towards
M. brassicae larvae in both cabbage leaf disc and droplet feeding
assays. High levels of mortality and reduced growth were observed
for second instar larvae exposed to discs coated with purified
fusion protein. The oral toxicity observed in these assays must be a
result of the Hv1a/GNA fusion protein, since GNA at a
comparable dose did not reduce survival (although a reduced
effect on larval growth was observed). These results are
comparable to previously published data for the oral insecticidal
Figure 3. Leaf disc assays. (A) Survival of M. brassicae larvae fed from second stadia on cabbage discs coated with purified recombinant GNA (0.2%
w/w) or Hv1a/GNA (0.2% w/w and 0.1% w/w) or on control PBS-coated discs (n=20 per treatment). (B) Mean weight of larvae recorded at day 10.
doi:10.1371/journal.pone.0039389.g003
Figure 4. Analysis of haemolymph and nerve chords. Immunoblot analysis using anti-GNA antibodies of (A) haemolymph samples extracted
from M. brassicae larvae 48 h after feeding on diet containing Hv1a/GNA (2 mg/5 g diet). ‘‘C’’ denotes control haemolymph (larvae fed on diet with
no added protein). Lanes 1 and 2 are replicates of pooled samples (3 larvae per sample); 15 ml of haemolymph was loaded in all cases. (B) Nerve chord
samples dissected from sixth stadium larvae that had been injected with 25 mg GNA (lanes 1–4) or Hv1a/GNA (lanes 5–8). Pooled samples were
extracted 3 h (lanes 1, 2, 5, and 6) or 5 h (lanes 3, 4, 7, and 8) post injection. Pooled samples (4 nerve chords per sample) were extracted directly in
40 ml SDS-sample buffer and 20 ml was loaded per lane. ‘‘C’’ denotes control nerve chord sample. In panels (A) and (B), S1 and S2 are 50 ng standards
of GNA and Hv1a/GNA respectively.
doi:10.1371/journal.pone.0039389.g004
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oleracea larvae [12].
The consumption of droplets containing 40 mg of Hv1a/GNA
fusion protein by fifth stadium larvae was seen to result in a
complete cessation of feeding and larvae appeared relatively
immobile, consistent with the previously described paralytic
activity of the toxin [1,9]. Larvae failed to survive to pupation
following droplet consumption of a total of 160 mg of fusion
protein over four days. By contrast, larvae exposed to droplets
containing an equivalent dose of Hv1a showed no evidence of
reduced feeding or paralysis and all survived to pupation. The
absence of oral toxicity for Hv1a contrasts with the previous results
reporting 100% mortality of Heliothis armigera and S. littoralis
exposed to transgenic tobacco expressing Hv1a [17]. One
possibility is that natural insecticidal compounds produced by
these plants might produce disturbances in the insect gut
epithelium and thereby act synergistically with Hv1a to improve
its oral activity. Khan and co-workers [17] also reported contact
insecticidal activity for Hv1a, although in their assays the fusion
protein was applied topically in a solution containing high levels of
Figure 5. Binding of GNA to nerve chords. (A) Intact nerve chord dissected from sixth stadium M. brassicae larvae. (B–F) Composite of partial
images of nerve tracts dissected from larvae injected with, or fed on, FITC-labelled proteins. Images were visualised with a fluorescent microscope
under FITC filter and captured in OpenLab. B: FITC-GNA; C: FITC-Hv1a/GNA; D: control FITC; E: FITC-ovalbumin; F: FITC-GNA; G: FITC-Hv1a/GNA. Scale
bar=2 mm in (A) and 200 mM in (B–E).
doi:10.1371/journal.pone.0039389.g005
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[18].
GNA Mediates Delivery of Hv1a to Insect CNS
Most spider toxins act peripherally at neuromuscular junctions
but Hv1a acts at sites within the central nervous system [1,8].
Bloomquist, 2003 previously demonstrated that Hv1a is able to
cross the nerve sheath; whereas Hv1a acted instantaneously in
Drosophila melanogaster nerve preparations that had been transected
to facilitate toxin penetration, an 18 minute delay in the blockage
of nerve firing occurred when intact nerve preparations were used
and this delay was consistent with the time taken to observe
paralysis following injection of the toxin. Surprisingly, Western
blot analysis of nerve chords dissected from insects injected with
GNA and Hv1a/GNA indicated that GNA binds to the central
nerve chord of lepidopteran larvae and is therefore capable of
mediating the delivery of Hv1a to sites of action within the CNS.
Further direct evidence for GNA localization to CNS was
provided by fluorescence imagery of nerve chords dissected from
larvae that had been injected with, or fed on, FITC-labelled
proteins. That GNA binds to mannose-containing membrane-
bound polypeptides was indicated by intense fluorescence of the
nerve chord sheath and also by reduced binding in tissues
extracted from insects injected with GNA that had been pre-
incubated with mannose.
Neurophysiological studies with cockroaches, lepidopteran and
dipteran larvae have indicated that Hv1a impairs ganglionic
neural transmission, rather than conductance along the nerve
chord. The characteristic delay in paralysis observed after
injection of the toxin is thought to be attributable to the time
required for the toxin to cross the nerve sheath and enter the CNS
[1,8]. The results presented here suggest that GNA may help to
localise covalently attached insecticidal neurotoxins, such as Hv1a,
to the CNS of exposed insects and thereby facilitate toxin action
within the CNS.
In conclusion, the data presented here indicates that GNA not
only mediates delivery of insecticidal peptides across the insect gut
but that it is also capable of delivering peptides to the insect central
nervous system. In the case of Hv1a, the massive improvement in
oral activity upon fusion to GNA can be attributed to both of these
properties. Many insecticidal peptides have been isolated from
arachnid venoms [9,19,20], and fusion to GNA would appear to
provide a general mechanism for dramatically enhancing their
oral activity. GNA-toxin fusion proteins could be used for crop
protection either as exogenously applied treatments or as
endogenous proteins expressed in transgenic plants or entomo-
pathogens.
Materials and Methods
Materials and Recombinant Techniques
General molecular biology protocols were as described in [21]
except where otherwise noted. Subcloning was carried out using
the TOPO cloning kit (pCR2.1 TOPO vector; Invitrogen). Pichia
pastoris SMD1168H (protease A deficient) strain, the expression
vector pGAPZaB, and Easycomp Pichia transformation kit were
from Invitrogen. Oligonucleotide primers were synthesised by
Sigma-Genosys Ltd. T4 polynucleotide kinase was from Fermen-
tas. Restriction endonucleases, T4 DNA ligase, and Pfu DNA
polymerase were supplied by Promega. Plasmid DNA was
prepared using Promega Wizard miniprepkits. GNA was pro-
duced as a recombinant protein in yeast using a clone generated as
previously described [22]. Anti-GNA antibodies (raised in rabbits),
were prepared by Genosys Biotechnologies, Cambridge, UK.
Anti-Hv1a polyclonal antibodies (raised in rabbits) were prepared
by the Institute of Medical and Veterinary Science, Adelaide,
Australia. Recombinant Hv1a was prepared as described previ-
ously [2,4].
All DNA sequencing was carried out using dideoxynucleotide
chain termination protocols on Applied Biosystems automated
DNA sequencers by the DNA Sequencing Service, School of
Biological and Biomedical Sciences, University of Durham, UK.
Sequences were checked and assembled using Sequencher
software running on Mac OS computers. The Hv1a/GNA
sequence has been deposited in Genbank (#1527166).
Assembly of expression constructs for production of
Hv1a/GNA fusion protein. The Hv1a amino acid sequence
(UniProtKB P56207) was used as the basis for assembly of a
synthetic Hv1a gene. Codon usage was optimised for expression in
yeast (www.yeastgenome.org/community/codonusage.shtml). The
coding strand was subdivided into two fragments and the
complementary strand was subdivided into three fragments, such
that the coding fragments overlapped the complementary strand
fragments by 21 bases. Five oligonucleotides based on these
fragments were synthesised and used to assemble the mature Hv1a
coding sequence (Table 1). All primers were individually 59-
phosphorylated using T4 polynucleotide kinase. An equimolar
solution of 100 pmol of each phosphorylated primer was boiled for
10 min to denature secondary structures, then the solution was
slowly cooled to room temperature (RT) to allow the primers to
anneal. After addition of T4 DNA ligase, annealed oligonucleo-
tides (in ligase buffer) were left to anneal for 15 h at 4uC. To
obtain sufficient DNA for cloning into the yeast expression vector
pGAPZaB, the Hv1a coding sequence was amplified by PCR
using primers containing 59 PstI and 39 NotI restriction sites.
Following amplification, gel purification and restriction digest, the
PCR product was ligated into a previously generated yeast
expression construct [14] containing the mature GNA coding
sequence (amino acids 1–105 derived from LECGNA2 cDNA;
[23]) to create the plasmid Hv1a/GNA-pGAPZaB. The sequence
of the Hv1a/GNA expression construct has been given the
accession number JQ898015 by GenBank.
Expression and Purification of Hv1a/GNA Fusion Protein
Plasmid Hv1a/GNA-pGAPZaB DNA was transformed into
chemically competent P. pastoris cells (strain SMD1168H) accord-
ing to protocols supplied by Invitrogen. Transformants were
selected by plating on medium containing zeocin (100 mg/ml). A
clone expressing recombinant Hv1a/GNA was selected for
production by bench-top fermentation by Western analysis using
anti-GNA (1:3300 dilution) antibodies of supernatants from small-
scale cultures grown at 30uC for 2–3 days in YPG medium (1% w/
v yeast extract; 2% w/v peptone; 4% v/v glycerol; 100 mg/ml
zeocin) (results not shown).
For protein production, P. pastoris cells expressing Hv1a/GNA
fusion protein or GNA encoding sequences were grown in a
BioFlo 110 laboratory fermenter. Briefly, 36100 ml YPG cultures
(grown for 2–3 days at 30uC with shaking) were used to inoculate
3 l of sterile minimal media supplemented with PTM1 trace salts
[24,25] Cultivation was conducted at 30uC, pH 4.5–5.0, 30%
dissolved oxygen (cascaded agitation 250–750 rpm) with a glycerol
feed (5–10 ml/h; 1.3 l over 72 h). Secreted proteins were
separated from cells by centrifugation (30 min at 7500 g,4 uC).
NaCl was added to the supernatant to a final concentration of
2 M. Recombinant proteins were purified by hydrophobic
interaction chromatography on a phenyl-Sepharose (Amersham
Pharmacia Biotech) column (1 cm dia., 25 ml), run at 2 ml/min.
After loading, the phenyl-Sepharose column was washed with 2 M
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60 min. Recombinant Hv1a/GNA eluted at ,1 M NaCl.
Fractions containing purified proteins (analysed by SDS-PAGE)
were then pooled, dialysed against distilled water and lyophilised.
Lyophilised fusion protein and GNA were subject to gel filtration
on Sephacryl S-200 columns (1.6 cm diameter, 90 cm length, flow
rate 0.3 ml/min) to remove high molecular weight yeast proteins
as described previously [14]. Fractions containing purified
recombinant proteins were again dialysed and lyophilised, or
desalted and concentrated using Microsep TM centrifugal
concentrators (VivaScience AG, Hannover, Germany).
Electrophoresis and Western Blotting
Proteins were routinely analysed by SDS-PAGE (17.5%
acrylamide gels). Samples were prepared by adding 56 SDS
sample buffer (containing 10% b-mercaptoethanol) and boiling for
10 min prior to loading. Gels were either stained with Coomassie
blue or transferred to nitrocellulose for Western blotting using a
Biorad Trans-blot SD semi dry transfer cell according to the
manufacturer’s recommendations. Western blotting of recombi-
nant proteins and larval samples (haemolymph and nerve chord)
using anti-GNA (1:3300 dilution) or anti-Hv1a (1:1000 dilution)
antibodies was carried out as described [26].
FITC Labelling
Recombinant GNA, Hv1a/GNA, and ovalbumin (control) were
fluorescently labelled with a 2:1 molar excess of fluorescein
isothiocyanate (FITC, Sigma). Recombinant proteins (1 ml) were
re-suspended at 2 mg/ml in 500 mM carbonate buffer pH 9.0
then incubated with 50 ml FITC (1 mg/ml in DMSO) with
rotation for 4 h at RT, under dark conditions. Samples were
dialysed against phosphate-buffered saline (PBS pH 7.4) at RT to
remove excess FITC. FITC labelling of Hv1a was unsuccessful,
presumably due to the scarcity of primary amines available for
FITC attachment.
Insect Rearing
M. brassicae were originally obtained from cultures held at the
Food and Environment Research Agency (FERA) and were reared
at the University of Durham continuously on artificial diet [27] at
22–25uC under a 16 h:8 h light:dark regime.
Injection Bioassays
Purified recombinant Hv1a peptide and Hv1a/GNA were
tested for biological activity by injecting 4–5 ml of aqueous samples
(lyophilised protein re-suspended in PBS) into newly eclosed fifth
stadium M. brassicae larvae (40–70 mg). For each concentration
tested, 10–20 larvae were injected and toxic effects were
monitored over 4 days. PBS was injected as a negative control.
Recombinant GNA is known to have no effect upon M. brassicae
larvae when injected at up to 200 mg/larva (unpublished data).
Feeding Bioassays
Droplet feeding assays: M. brassicae. Several droplet-
feeding assays were conducted to assess the oral activity of Hv1a/
GNA towards M. brassicae fourth and fifth stadium larvae. Final
sample numbers were relatively small (n=7–8 per treatment) as
larvae were reluctant to ingest daily droplets and insects that did
not consume a full 5-ml droplet were discarded from data sets. Two
representative assays are described herein.
Droplet assay 1. Newly moulted fifth stadium larvae were
fed daily for 4 days with a 5-ml droplet containing 40 mg of Hv1a/
GNA or 9.6 mg of Hv1a toxin in 16PBS and 10% sucrose
solution. Control larvae were fed on droplets containing 40 mg
bovine serum albumin (BSA). To encourage droplet consumption,
larvae were starved for ,2–3 h prior to feeding. Larval weight was
recorded daily ,1 h after droplet feeding. Treated larvae were
placed individually in ventilated plastic pots (250 ml) with
standard artificial diet. After 4 days of daily droplet feeding,
larvae were maintained on optimal diet until the onset of pupation.
Droplet assay 2. Newly moulted fifth stadium larvae were
fed on a single 5-ml droplet containing 40 mg of Hv1a/GNA or
40 mg BSA (control) in 16PBS and 10% sucrose. Larvae were
maintained as described above and weights recorded daily for 10
days.
Leaf disc assays: M. brassicae. The oral activity of Hv1a/
GNA was further tested by feeding second instar M. brassicae
larvae on cabbage (Brassicae oleracea) discs coated with purified
fusion protein at concentrations of 0.2% w/w and 0.1% w/w (i.e.,
10 mg/5 g and 5 mg/5 g leaf wet weight, respectively) or
recombinant GNA at 0.2% w/w. Discs (,20 mm dia., 140 mg
fresh wt.) were prepared by adding droplets of protein (re-
suspended in 0.56PBS and 0.1% v/v Tween) onto upper and
lower surfaces of discs and air dried. Control discs were prepared
with 0.56PBS, 0.1% v/v Tween. Larvae were reared from hatch
for 72 h on non-treated cabbage and then placed into ventilated
plastic pots (250 ml) containing coated leaf discs and moist filter
paper to prevent dessication. Freshly prepared discs were provided
every 2–3 days. Two replicates of 10 larvae per treatment were
assayed. Survival was recorded for 10 days. To minimise handling
time, larval weights were recorded on days 4, 7, and 10.
Haemolymph Extraction and Nerve Chord Dissection
Haemolymph samples were extracted and prepared for Western
analysis [12] from day 2 fifth instar larvae fed for 24 h on diet
containing Hv1a/GNA at 2 mg/5 g wet wt. (,2% dietary
protein). Typically, aliquots of two replicate samples containing
pooled haemolymph (3–5 larva per sample) were run on SDS-
PAGE gels and analysed by immunoblotting using anti-GNA
antibodies. To investigate if GNA or Hv1a/GNA were localized to
the CNS after oral delivery or injection, nerve chords were
analysed by one of two methods. Nerve chords were dissected
from sixth stadium larvae 4–24 h after injection or after being fed
on droplets containing 20–50 mg GNA or fusion protein. Nerve
tissue was subsequently analysed by Western blotting or visualised
by fluorescent microscopy (section 2.11). Nerve chords were
dissected as follows. Pre-chilled larvae were immersed in ice-cold
distilled water prior to making a ventral incision from the tail to
the head capsule. The resulting flaps of cuticle were fixed with pins
into dissecting wax. The entire gut was carefully removed and the
head capsule split to expose the terminal brain ganglia. Intact
nerve chord and brain was then separated (using scissors) from the
cuticle and head capsule and immersed immediately either in SDS
sample buffer for Western analysis or in 3.7% w/v paraformal-
dehyde (PFA) for microscopy.
Fluorescent Microscopy
Nerve chords were extracted from sixth stadium larvae 4 h after
injection of ,10 mg of FITC-labelled GNA or FITC-labelled
Hv1a/GNA. Larvae were also injected with GNA that had been
pre-incubated for 1 h at RT with 0.2 M mannose (methyl a-D-
mannopyranoside). Nerve chords were also extracted from larvae
after feeding on artificial diet containing FITC-labelled GNA or
FITC-labelled Hv1a/GNA such that each larva consumed 50–
100 mg labeled protein. Control treatments included FITC-
labelled ovalbumin (10 mg per injection, 50–100 mg by ingestion)
and FITC alone (0.5 mg per injection, 2.5 mg by ingestion).
Orally Active Insecticidal Fusion Protein
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chords were washed 36in ice cold PBS (15 min per wash),
mounted onto glass slides and overlaid with coverslips. Nerve
chords were visualized using a fluorescent microscope (Nikon)
under FITC filter (absorbance 494 nm; emission 521 nm) and
images were captured in OpenLab.
Statistical Analysis
Data were analysed using Prism 5.0 (GraphPad Software Inc.).
Kaplan–Meier insect survival curves were compared using
Mantel–Cox log-rank tests. Insect weights were compared using
either Student’s t-tests or one-way analysis of variance (ANOVA),
followed by Tukey–Kramer post hoc means separation. The
accepted level of significance was P,0.05 in all cases.
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